{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:34:51Z","timestamp":1790861691409,"version":"4.1.0"},"reference-count":23,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype is linked to frequent exacerbations and increased oral corticosteroid (OCS) use. Mepolizumab, an anti\u2013IL-5 monoclonal antibody, has shown efficacy in eosinophilic airway disease. This study assessed its real-life effectiveness in COPD patients with frequent OCS-requiring exacerbations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate the effectiveness of mepolizumab in reducing exacerbations and corticosteroid use in eosinophilic COPD patients in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective, single-centre cohort study with two-year follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The study included 13 consecutive COPD patients treated with mepolizumab (100\u2009mg SC every 4\u2009weeks) from 2020 to 2022 and followed for two years. Inclusion required \u2a7e2 OCS-treated exacerbations or maintenance OCS use in the prior year and blood eosinophils\u2009&gt;\u2009300 cells\/\u00b5L. Response was defined as a \u2a7e50% reduction in annual OCS-requiring exacerbations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At one year, 9 of 13 patients (69%) were responders. Median annual moderate-to-severe exacerbations decreased from 4.0 (IQR: 1.5\u201310.0) to 1.0 (IQR: 0.0\u20132.0;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.007). COPD-related hospitalizations declined from 2.0 (IQR: 0.0\u20134.0) to 0.0 (IQR: 0.0\u20130.0;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.007). Among the eight patients who continued therapy into the second year, moderate-to-severe exacerbations declined from a median of 5.0 (IQR: 3.0\u201312.0) at baseline to 2.0 (IQR: 1.0\u20132.8) in year one and 0.5 (IQR: 0.0\u20132.8) in year two (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.018), representing 60% and 90% reductions, respectively. Hospitalisations dropped from 2.0 (IQR: 0.3\u20134.0) to 0.0 (IQR: 0.0\u20130.0) in both years (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.008). Maintenance OCS was discontinued in 2 of 4 patients (50%) after one year. Responders did not differ from non-responders in type 2 markers, but tended to have a higher baseline frequency of exacerbations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Mepolizumab significantly reduced exacerbations and hospitalizations in eosinophilic COPD patients with frequent OCS use. A 69% response rate at one year and sustained benefit in the second year support its role in this difficult-to-treat population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17534666251414352","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:58:56Z","timestamp":1770983936000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Mepolizumab for eosinophilic COPD with frequent exacerbations: single-centre real-world experience in a phenotype-directed approach"],"prefix":"10.1177","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6053-7406","authenticated-orcid":false,"given":"Irena","family":"\u0160arc","sequence":"first","affiliation":[{"name":"University Clinic of Respiratory and Allergic Diseases Golnik, Golnik 36, Golnik 4204, Slovenia Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Morgan","sequence":"additional","affiliation":[{"name":"University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Po\u017eek","sequence":"additional","affiliation":[{"name":"University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7261-6689","authenticated-orcid":false,"given":"Peter","family":"Kopa\u010d","sequence":"additional","affiliation":[{"name":"University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01273-9"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/17534666241308408"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201104-0597OC"},{"key":"e_1_3_4_5_2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease: 2025 report https:\/\/goldcopd.org\/2025-gold-report\/ (2024 accessed 19 March 2025)."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S378649"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.04.013"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.11.021"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708208"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413181"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905248"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S294333"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00409-0"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401304"},{"key":"e_1_3_4_15_2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease: 2022 report https:\/\/goldcopd.org (2021 accessed 30 October 2025)."},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.12120385"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.2065"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"issue":"6","key":"e_1_3_4_19_2","first-page":"639","article-title":"Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: a biologics outlook","volume":"208","author":"Rabe KF","year":"2023","unstructured":"Rabe KF, Rennard S, Martinez FJ, et al. Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: a biologics outlook. Am J Respir Crit Care Med 2023; 208(6): 639\u2013641.","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01875-2024"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020639"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202308-1436OC"},{"key":"e_1_3_4_23_2","unstructured":"AstraZeneca. Update on RESOLUTE Phase III trial for Fasenra in chronic obstructive pulmonary disease https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/update-on-resolute-phase-iii-trial.html (17 September 2025 accessed 8 December 2025)."},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219781"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666251414352","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17534666251414352","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666251414352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T11:56:23Z","timestamp":1771242983000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17534666251414352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":23,"alternative-id":["10.1177\/17534666251414352"],"URL":"https:\/\/doi.org\/10.1177\/17534666251414352","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/17534666251414352\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251414352\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251414352\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251414352\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251414352\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251414352\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251414352\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251414352\/v1\/review1","asserted-by":"object"}]},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"17534666251414352"}}